9月22日 - ** 药物开发商MBX生物科学公司MBX.O的股票在盘前交易中大涨84%，达到18.5美元
** MBX称 (link)，其每周一次的试验性药物坎武帕肽在针对慢性甲状旁腺功能减退症（一种导致低血钙的激素紊乱）成人患者的中期试验中达到了主要目标。
** 在为期12周的研究中，63%服用坎武帕肽的患者将血钙控制在正常范围内，无需服用活性维生素D或每天服用600毫克以上的钙补充剂，而服用安慰剂的患者仅为31%，差异具有统计学意义
** 公司表示，该药物耐受性良好，未出现严重不良事件
** MBX计划于2026年开始后期试验
** 截至上一交易日收盘，MBX股价年累计下跌45.7
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.